UYGUN, K. Et Al. 2013. XELIRI plus bevacizumab compared with FOLFIRI plus bevacizumab as first-line setting in patients with metastatic colorectal cancer: experiences at two-institutions.. Asian Pacific journal of cancer prevention : APJCP , vol.14, no.4 , 2283-8.

UYGUN, K., Bilici, A., Kaya, S., Ustaalioglu, B. B. O., Yildiz, R., Temiz, S., ... Seker, M.(2013). XELIRI plus bevacizumab compared with FOLFIRI plus bevacizumab as first-line setting in patients with metastatic colorectal cancer: experiences at two-institutions.. Asian Pacific journal of cancer prevention : APJCP , vol.14, no.4, 2283-8.

UYGUN, KAZIM Et Al. "XELIRI plus bevacizumab compared with FOLFIRI plus bevacizumab as first-line setting in patients with metastatic colorectal cancer: experiences at two-institutions.," Asian Pacific journal of cancer prevention : APJCP , vol.14, no.4, 2283-8, 2013

UYGUN, KAZIM Et Al. "XELIRI plus bevacizumab compared with FOLFIRI plus bevacizumab as first-line setting in patients with metastatic colorectal cancer: experiences at two-institutions.." Asian Pacific journal of cancer prevention : APJCP , vol.14, no.4, pp.2283-8, 2013

UYGUN, K. Et Al. (2013) . "XELIRI plus bevacizumab compared with FOLFIRI plus bevacizumab as first-line setting in patients with metastatic colorectal cancer: experiences at two-institutions.." Asian Pacific journal of cancer prevention : APJCP , vol.14, no.4, pp.2283-8.

@article{article, author={KAZIM UYGUN Et Al. }, title={XELIRI plus bevacizumab compared with FOLFIRI plus bevacizumab as first-line setting in patients with metastatic colorectal cancer: experiences at two-institutions.}, journal={Asian Pacific journal of cancer prevention : APJCP}, year=2013, pages={2283-8} }